Intuitive Surgical Expands Direct Operational Presence in Europe

Core Insights - Intuitive Surgical (ISRG) has completed the acquisition of the da Vinci and Ion distribution business in Europe to initiate direct operations in the region [1][8] - The integration of the acquired business into ISRG's European commercial and marketing organization is underway, with leadership from senior vice president Dirk Barten [2] Company Performance - ISRG shares have decreased by 1.2% since the acquisition announcement, while the company has seen a 6.6% increase in share price over the past six months, contrasting with a 3.8% decline in the industry [3] - The company has placed 342 da Vinci surgical systems in Europe in 2025, up from 309 in 2024, indicating steady demand growth [6][8] Market Expansion - The total installed base of da Vinci surgical systems in Italy, Spain, and Portugal exceeded 470 by the end of 2025, with the Ion platform recently launched in Italy and Spain [5][10] - The share of patients treated in ex-U.S. markets has risen from 23% in 2015 to 35% in 2025, driven by growth in Europe and Asia [6] Technological Advancements - The Ion system has significantly reduced the time to start lung cancer treatment from over 200 days to 28 days, potentially improving patient survival rates [10] - ISRG received European approval for its advanced da Vinci 5 robotic surgery system, which has seen strong adoption in the U.S. market [9] Industry Prospects - The surgical robots market in Europe was valued at $2.10 billion in 2024 and is projected to grow at a CAGR of 14%, reaching $5.21 billion by 2031, driven by the demand for minimally invasive procedures [12] - ISRG's strong presence in the robotic surgery market positions it well to benefit from this anticipated growth [13]